InnoCure Therapeutics is developing PROTACs to destroy unwanted pathogenic proteins
InnoCure Therapeutics is developing PROTACs to destroy unwanted pathogenic proteins. The company combines biological expertise, AI processing, and medicinal chemistry skills to develop TDbUM, a unique drug discovery platform to analyze over 20,000 human proteins, identifying 'undruggable' targets and discovering binders for new E3 Ligases to expand therapeutic targets and increase safety profiles.